The dark side of SOX2

Cancer - A comprehensive overview

Erin L. Wuebben, A Angie Rizzino

Research output: Contribution to journalReview article

44 Citations (Scopus)

Abstract

The pluripotency-associated transcription factor SOX2 is essential during mammalian embryogenesis and later in life, but SOX2 expression can also be highly detrimental. Over the past 10 years, SOX2 has been shown to be expressed in at least 25 different cancers. This review provides a comprehensive overview of the roles of SOX2 in cancer and focuses on two broad topics. The first delves into the expression and function of SOX2 in cancer focusing on the connection between SOX2 levels and tumor grade as well as patient survival. As part of this discussion, we address the developing connection between SOX2 expression and tumor drug resistance. We also call attention to an under-appreciated property of SOX2, its levels in actively proliferating tumor cells appear to be optimized to maximize tumor growth - too little or too much SOX2 dramatically alters tumor growth. The second topic of this review focuses on the exquisite array of molecular mechanisms that control the expression and transcriptional activity of SOX2. In addition to its complex regulation at the transcriptional level, SOX2 expression and activity are controlled carefully by microRNAs, long non-coding RNAs, and post-translational modifications. In the Conclusion and Future Perspectives section, we point out that there are still important unanswered questions. Addressing these questions is expected to lead to new insights into the functions of SOX2 in cancer, which will help design novels strategies for more effectively treating some of the most deadly cancers.

Original languageEnglish (US)
Pages (from-to)44917-44943
Number of pages27
JournalOncotarget
Volume8
Issue number27
DOIs
StatePublished - Jan 1 2017

Fingerprint

Neoplasms
SOXB1 Transcription Factors
Long Noncoding RNA
Post Translational Protein Processing
Growth
MicroRNAs
Drug Resistance
Embryonic Development
Survival

Keywords

  • Cancer
  • Cancer stem cell markers
  • SOX2
  • Tumor progression
  • Tumor-initiating cells

ASJC Scopus subject areas

  • Oncology

Cite this

The dark side of SOX2 : Cancer - A comprehensive overview. / Wuebben, Erin L.; Rizzino, A Angie.

In: Oncotarget, Vol. 8, No. 27, 01.01.2017, p. 44917-44943.

Research output: Contribution to journalReview article

Wuebben, Erin L. ; Rizzino, A Angie. / The dark side of SOX2 : Cancer - A comprehensive overview. In: Oncotarget. 2017 ; Vol. 8, No. 27. pp. 44917-44943.
@article{479bdea41ac1492db594b8a1f8fb3249,
title = "The dark side of SOX2: Cancer - A comprehensive overview",
abstract = "The pluripotency-associated transcription factor SOX2 is essential during mammalian embryogenesis and later in life, but SOX2 expression can also be highly detrimental. Over the past 10 years, SOX2 has been shown to be expressed in at least 25 different cancers. This review provides a comprehensive overview of the roles of SOX2 in cancer and focuses on two broad topics. The first delves into the expression and function of SOX2 in cancer focusing on the connection between SOX2 levels and tumor grade as well as patient survival. As part of this discussion, we address the developing connection between SOX2 expression and tumor drug resistance. We also call attention to an under-appreciated property of SOX2, its levels in actively proliferating tumor cells appear to be optimized to maximize tumor growth - too little or too much SOX2 dramatically alters tumor growth. The second topic of this review focuses on the exquisite array of molecular mechanisms that control the expression and transcriptional activity of SOX2. In addition to its complex regulation at the transcriptional level, SOX2 expression and activity are controlled carefully by microRNAs, long non-coding RNAs, and post-translational modifications. In the Conclusion and Future Perspectives section, we point out that there are still important unanswered questions. Addressing these questions is expected to lead to new insights into the functions of SOX2 in cancer, which will help design novels strategies for more effectively treating some of the most deadly cancers.",
keywords = "Cancer, Cancer stem cell markers, SOX2, Tumor progression, Tumor-initiating cells",
author = "Wuebben, {Erin L.} and Rizzino, {A Angie}",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.16570",
language = "English (US)",
volume = "8",
pages = "44917--44943",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "27",

}

TY - JOUR

T1 - The dark side of SOX2

T2 - Cancer - A comprehensive overview

AU - Wuebben, Erin L.

AU - Rizzino, A Angie

PY - 2017/1/1

Y1 - 2017/1/1

N2 - The pluripotency-associated transcription factor SOX2 is essential during mammalian embryogenesis and later in life, but SOX2 expression can also be highly detrimental. Over the past 10 years, SOX2 has been shown to be expressed in at least 25 different cancers. This review provides a comprehensive overview of the roles of SOX2 in cancer and focuses on two broad topics. The first delves into the expression and function of SOX2 in cancer focusing on the connection between SOX2 levels and tumor grade as well as patient survival. As part of this discussion, we address the developing connection between SOX2 expression and tumor drug resistance. We also call attention to an under-appreciated property of SOX2, its levels in actively proliferating tumor cells appear to be optimized to maximize tumor growth - too little or too much SOX2 dramatically alters tumor growth. The second topic of this review focuses on the exquisite array of molecular mechanisms that control the expression and transcriptional activity of SOX2. In addition to its complex regulation at the transcriptional level, SOX2 expression and activity are controlled carefully by microRNAs, long non-coding RNAs, and post-translational modifications. In the Conclusion and Future Perspectives section, we point out that there are still important unanswered questions. Addressing these questions is expected to lead to new insights into the functions of SOX2 in cancer, which will help design novels strategies for more effectively treating some of the most deadly cancers.

AB - The pluripotency-associated transcription factor SOX2 is essential during mammalian embryogenesis and later in life, but SOX2 expression can also be highly detrimental. Over the past 10 years, SOX2 has been shown to be expressed in at least 25 different cancers. This review provides a comprehensive overview of the roles of SOX2 in cancer and focuses on two broad topics. The first delves into the expression and function of SOX2 in cancer focusing on the connection between SOX2 levels and tumor grade as well as patient survival. As part of this discussion, we address the developing connection between SOX2 expression and tumor drug resistance. We also call attention to an under-appreciated property of SOX2, its levels in actively proliferating tumor cells appear to be optimized to maximize tumor growth - too little or too much SOX2 dramatically alters tumor growth. The second topic of this review focuses on the exquisite array of molecular mechanisms that control the expression and transcriptional activity of SOX2. In addition to its complex regulation at the transcriptional level, SOX2 expression and activity are controlled carefully by microRNAs, long non-coding RNAs, and post-translational modifications. In the Conclusion and Future Perspectives section, we point out that there are still important unanswered questions. Addressing these questions is expected to lead to new insights into the functions of SOX2 in cancer, which will help design novels strategies for more effectively treating some of the most deadly cancers.

KW - Cancer

KW - Cancer stem cell markers

KW - SOX2

KW - Tumor progression

KW - Tumor-initiating cells

UR - http://www.scopus.com/inward/record.url?scp=85021828163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021828163&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.16570

DO - 10.18632/oncotarget.16570

M3 - Review article

VL - 8

SP - 44917

EP - 44943

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 27

ER -